Regulatory filings present that Terns finally accepted a suggestion 15% decrease than a earlier proposal as 4 firms vied for rights to the coveted leukemia drug developer.
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the most recent breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s tendencies at the moment: learn extra, subscribe to our publication, and turn into a part of the NextTech group at NextTech-news.com
